Understanding factors that affect treatment differences in multiple myeloma
Official title: Modifiable Determinants of Disparities in Multiple Myeloma Treatment Patterns
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11042206 · Data updated 2026-11-12
This study is looking at how things like weight and access to healthcare can affect the treatment of multiple myeloma, especially for Black patients who often face more challenges, and it aims to find ways to make treatment better and more accessible for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $248,999 |
| NIH project number | 5R00CA277136-03 |
| Project ID | NIH-11042206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include Black individuals diagnosed with multiple myeloma, as well as those affected by obesity-related health disparities.
✕Less likely to help
Patients with multiple myeloma who do not belong to the targeted demographic groups or who have other unrelated health conditions may not benefit from this research.
What this research studies
This research investigates the various factors that contribute to disparities in treatment for multiple myeloma, particularly focusing on how modifiable elements like obesity and access to care can influence outcomes. The study aims to analyze electronic health records and large datasets to identify patterns and barriers faced by patients, especially within Black communities who are disproportionately affected by this cancer. By engaging with healthcare providers and policymakers, the research seeks to develop strategies to improve treatment access and effectiveness for all patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment access and outcomes for patients with multiple myeloma, particularly among underserved populations.
How similar studies have gone: Previous research has shown success in addressing cancer treatment disparities through targeted interventions, indicating that this approach has potential for meaningful impact.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Gasoyan, Hamlet — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Gasoyan, Hamlet
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.